Ftse Mib
33.707,21
-0,38%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.764,53
-0,06%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Viridian Therapeutics Inc (VRDN) Viridian Therapeutics Inc (VRDN) Notizie

VRDN

Viridian Therapeutics (VRDN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VRDN
DataOraFonteTitoloSimboloCompagnia
11/06/202412:00Business WireViridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
10/06/202414:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VRDNViridian Therapeutics Inc
06/06/202422:01Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
31/05/202414:00Business WireViridian Therapeutics Announces Participation in Upcoming June Investor ConferencesNASDAQ:VRDNViridian Therapeutics Inc
10/05/202414:00Business WireViridian Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:VRDNViridian Therapeutics Inc
08/05/202413:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRDNViridian Therapeutics Inc
08/05/202413:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
08/05/202413:00Business WireViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
29/04/202414:00Business WireViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VRDNViridian Therapeutics Inc
05/03/202414:00Business WireViridian Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:VRDNViridian Therapeutics Inc
28/02/202422:10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRDNViridian Therapeutics Inc
27/02/202422:01Business WireViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VRDNViridian Therapeutics Inc
16/02/202414:00Business WireViridian Therapeutics Appoints Jennifer Tousignant as Chief Legal OfficerNASDAQ:VRDNViridian Therapeutics Inc
15/02/202402:28Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
14/02/202422:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
14/02/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
06/02/202422:01Business WireViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
24/01/202423:12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:VRDNViridian Therapeutics Inc
19/01/202422:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRDNViridian Therapeutics Inc
18/01/202404:00Business WireViridian Therapeutics Announces Pricing of Public Offering of Shares of Common StockNASDAQ:VRDNViridian Therapeutics Inc
17/01/202422:01Business WireViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockNASDAQ:VRDNViridian Therapeutics Inc
08/01/202414:00Business WireViridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
04/01/202414:00Business WireViridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
18/12/202317:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRDNViridian Therapeutics Inc
18/12/202313:00Business WireViridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
08/12/202322:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VRDNViridian Therapeutics Inc
30/11/202322:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VRDNViridian Therapeutics Inc
21/11/202314:00Business WireViridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:VRDNViridian Therapeutics Inc
13/11/202322:01Business WireViridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRDNViridian Therapeutics Inc
08/11/202314:00Business WireViridian Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:VRDNViridian Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VRDN

La tua Cronologia

COIN
EDGETH
Edgeware
ASX
SULKOR
LSE
62KC
Arran 47 A
NASDAQ
ETFCD
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network